Lantern Pharma Reports Q2 2026 Financials and Clinical Progress
Lantern Pharma (LTRN) reported its second-quarter financial performance for 2026, highlighting a net loss of $7.1 million or $0.57 per share compared to the prior year's $4.3 million. The company attributed this increase in losses partly to noncash warrant liabilities valued at $3.6 million due to rising stock prices during the quarter. Despite financial challenges, Lantern Pharma made notable progress on its clinical pipeline. LP-300 demonstrated a median progression-free survival of 8.9 months for EGFR exon 21 L858R patients and showed strong hazard ratios indicating potential therapeutic benefits in specific genetic subgroups. The company also advanced trials with LP-184, enrolling patients across bladder cancer and triple-negative breast cancer indications. Lantern Pharma emphasized its AI-driven drug discovery model as a key differentiator, enabling faster development timelines (2–3 years) and lower costs ($2M–$3M per program). The company also holds four priority review vouchers potentially worth $150 million to $200 million each. CFO David Margrave noted the need for additional capital raises or collaborations to extend operating runway.
Topics: clinical_trials financial_performance pharmaceuticals